SCHEDULE 13D/A: Oncology Institute Investor Group Reduces Stake Below 5% Following Private Placement Dilution
Beneficial Ownership Update
Ravi Sarin and OncologyCare Partners, LLC have ceased to be beneficial owners of more than 5% of The Oncology Institute, Inc.'s common stock due to dilution from a recent private placement.
Summary
- Ravi Sarin and OncologyCare Partners, LLC (collectively, the "Reporting Persons") have filed an Amendment No. 1 to their Schedule 13D, indicating they are no longer beneficial owners of more than 5% of The Oncology Institute, Inc.'s Common Stock.
- As of March 26, 2025, the Reporting Persons beneficially own 4,109,771 shares, representing 4.7% of the Issuer's outstanding Common Stock.
- This reduction in ownership below the 5% threshold is primarily due to dilution caused by The Oncology Institute, Inc.'s issuance of 12,006,510 shares in a private placement on March 26, 2025.
- The total outstanding shares of The Oncology Institute, Inc. used for calculation are 87,759,739, which includes 75,753,229 shares outstanding as of March 10, 2025, plus the 12,006,510 shares from the private placement.
- This filing serves as an 'exit filing' for the Reporting Persons, signifying their reduced stake.
- Ravi Sarin, who is the sole managing member of OncologyCare Holdings, LLC (which manages OncologyCare Partners), resigned from the Issuer's Board of Directors, including all committee positions, effective August 31, 2023.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of a change in beneficial ownership due to dilution from a capital raise. It does not convey a strong positive or negative sentiment, but rather a neutral reporting of events.
Positives
- The Oncology Institute, Inc. successfully completed a private placement, raising capital by issuing 12,006,510 shares of Common Stock.
Negatives
- Existing shareholders, including the Reporting Persons, experienced dilution of their ownership percentage due to the issuance of new shares in the private placement.
Risks
- Dilution of existing shareholder value due to the issuance of new shares in a private placement.
Future Outlook
This document primarily reports a change in beneficial ownership and does not provide explicit forward-looking statements or guidance from the Reporting Persons regarding the Issuer's future operations or financial performance.
Management Comments
- Ravi Sarin resigned, effective immediately, as a director of the Board of Directors of the Issuer, including any positions held as a member of any committee of the Board, on August 31, 2023.
Industry Context
The filing reflects a common occurrence in the public markets where significant shareholders' stakes can be diluted by subsequent capital raises, such as private placements. This is particularly relevant in growth-oriented sectors like healthcare and oncology, where companies often seek additional funding for expansion, research, or operational needs. The private placement indicates the company's ongoing efforts to secure capital, which is a typical activity for companies in the healthcare innovation space.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director, Board of Directors and Committee Member | Ravi Sarin | NA | 2023-08-31 | Resignation |
Legal Proceedings
- Neither the Reporting Persons nor OncologyCare Holdings have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) in the last five years.
- Neither the Reporting Persons nor OncologyCare Holdings have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activity subject to, federal or state securities laws or finding any violations with respect to such laws in the last five years.
Stakeholder Impact
- Shareholders: Existing shareholders experienced dilution of their ownership percentage due to the issuance of new shares in the private placement. The Reporting Persons' stake was reduced below 5%.
Next Steps
- The filing constitutes an 'exit filing' for the Reporting Persons, indicating no further reporting obligations under Schedule 13D unless their beneficial ownership again exceeds 5%.
Key Dates
| Date | Description |
|---|---|
| 2021-11-18 | Date of the Issuer's business combination with OncologyCare Partners, as reported in the Issuer's Form 8-K (amended November 19, 2021). |
| 2021-11-22 | Date of the original Schedule 13D filing with the SEC. |
| 2023-08-31 | Effective date of Ravi Sarin's resignation as a director of the Issuer's Board of Directors. |
| 2025-03-10 | Date as of which 75,753,229 shares of common stock of the Issuer were outstanding, as reported in the Issuer's Annual Report on Form 10-K. |
| 2025-03-26 | Date of the event requiring this filing; issuance of 12,006,510 shares in a private placement by the Issuer, leading to dilution of the Reporting Persons' stake. |
| 2025-03-26 | Date of the Issuer's Annual Report on Form 10-K filing with the SEC. |
| 2025-03-27 | Date of the Issuer's Current Report on Form 8-K filing with the SEC, disclosing the private placement. |
| 2025-04-23 | Date of signing for this Amendment No. 1 to Schedule 13D. |
Keywords
Oncology Institute, Ravi Sarin, OncologyCare Partners, Schedule 13D, Beneficial Ownership, Private Placement, Share Dilution, SEC Filing, Investment Firm, Healthcare, Oncology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.